140 related articles for article (PubMed ID: 11039459)
1. Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG.
Hoefnagel CA; Taal BG; Sivro F; Boot H; Valdes Olmos RA
Nucl Med Commun; 2000 Aug; 21(8):755-61. PubMed ID: 11039459
[TBL] [Abstract][Full Text] [Related]
2. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
3. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue.
Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B
Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
Brogsitter C; Pinkert J; Bredow J; Kittner T; Kotzerke J
J Nucl Med; 2005 Dec; 46(12):2112-6. PubMed ID: 16330578
[TBL] [Abstract][Full Text] [Related]
5. Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG): pharmacological MIBG, 131I-labelled MIBG and the combination.
Zuetenhorst H; Taal BG; Boot H; Valdes Olmos R; Hoefnagel C
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1157-64. PubMed ID: 10524647
[TBL] [Abstract][Full Text] [Related]
6. Role of [131I]metaiodobenzylguanidine therapy in carcinoids.
Hoefnagel CA; Taal BG; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):346-8. PubMed ID: 1726678
[TBL] [Abstract][Full Text] [Related]
7. Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours.
Zuetenhorst JM; Valdes Olmos RA; Muller M; Hoefnagel CA; Taal BG
Endocr Relat Cancer; 2004 Sep; 11(3):553-61. PubMed ID: 15369454
[TBL] [Abstract][Full Text] [Related]
8. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.
Taal BG; Hoefnagel CA; Valdes Olmos RA; Boot H; Beijnen JH
J Clin Oncol; 1996 Jun; 14(6):1829-38. PubMed ID: 8656251
[TBL] [Abstract][Full Text] [Related]
9. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
10. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours.
Nocaudie-Calzada M; Huglo D; Carnaille B; Proye C; Marchandise X
Eur J Nucl Med; 1996 Nov; 23(11):1448-54. PubMed ID: 8854840
[TBL] [Abstract][Full Text] [Related]
11. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
13. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours.
Taal BG; Hoefnagel CA; Valdés Olmos RA; Boot H
Eur J Cancer; 1996 Oct; 32A(11):1924-32. PubMed ID: 8943676
[TBL] [Abstract][Full Text] [Related]
14. [Role of 131I-metaiodobenzylguanidine scintigraphy in the diagnosis of intestinal carcinoids].
Bihl H; Sautter-Bihl ML; Wilhelm KR; Kimmig B
Nuklearmedizin; 1987 Dec; 26(6):263-7. PubMed ID: 3438170
[TBL] [Abstract][Full Text] [Related]
15. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET.
Menzel C; Graichen S; Berner U; Risse JH; Diehl M; Döbert N; Hamscho N; Grünwald F
Acta Med Austriaca; 2003; 30(2):37-40. PubMed ID: 12752086
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman J; Onaitis MW; Tyler DS; Olson JA
Cancer; 2004 Nov; 101(9):1987-93. PubMed ID: 15455358
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ
Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174
[TBL] [Abstract][Full Text] [Related]
19. Tumour size: the only predictive factor for 131I MIBG uptake in phaeochromocytoma and paraganglioma.
Nguyen HH; Proye CA; Carnaille B; Combemale F; Pattou FN; Huglo D
Aust N Z J Surg; 1999 May; 69(5):350-3. PubMed ID: 10353549
[TBL] [Abstract][Full Text] [Related]
20. [Contribution of 131I MIBG scintigraphy in the diagnosis of carcinoid tumors of the digestive tract. Experience of 14 cases].
Siproudhis L; Lescouarc'h J; Bretagne JF; Bourguet P; Raoul JL; Etienne PL; Herry JY; Gosselin M
Gastroenterol Clin Biol; 1991; 15(11):789-93. PubMed ID: 1769467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
